The global somatostatin analogs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of endocrine disorders and rising demand for somatostatin analogs in emerging economies such as China and India.
Octreotide, lanreotide, pasireotide are the three types of somatostatin analogs available in the market. Octreotide is used for treating acromegaly and carcinoid syndrome whereas lanreotide and pasireotide are used for treating neuroendocrine tumor (NET) patients with cushing syndrome or acromegaly respectively. The application segment includes acromegaly, carcinoid syndrome, neuroendocrine tumor (NET), cushing syndrome which are further classified into North America, Latin America, Europe, Asia Pacific and Middle East & Africa regions respectively.
Some Of The Growth Factors Of This Market:
- The Somatostatin Analogs market is driven by the increasing prevalence of chronic diseases such as diabetes and obesity, which are major risk factors for cancer.
- Increasing awareness about the benefits of Somatostatin Analogs in cancer treatment will drive the growth of this market.
- Increasing number of clinical trials on Somatostatin Analogs will provide opportunities for new product launches and innovations in this market.
- Growing geriatric population base will also fuel the growth of this market.
Industry Growth Insights published a new data on “Somatostatin Analogs Market”. The research report is titled “Somatostatin Analogs Market research by Types (Octreotide, Lanreotide, Pasireotide), By Applications (Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others), By Players/Companies Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical, ...”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Somatostatin Analogs Market Research Report
By Type
Octreotide, Lanreotide, Pasireotide
By Application
Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others
By Companies
Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Somatostatin Analogs Market Report Segments:
The global Somatostatin Analogs market is segmented on the basis of:
Types
Octreotide, Lanreotide, Pasireotide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Peptron
- Chiasma
- Ipsen Biopharmaceutical
- ...
Highlights of The Somatostatin Analogs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Octreotide
- Lanreotide
- Pasireotide
- By Application:
- Acromegaly
- Carcinoid Syndrome
- Neuroendocrine Tumor
- Cushing Syndrome
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Somatostatin Analogs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Somatostatin analogs are medications that are similar to somatostatin, but they have different chemical structures. These drugs can be used to treat a variety of conditions, including diabetes and obesity.
Some of the key players operating in the somatostatin analogs market are Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical.
The somatostatin analogs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Somatostatin Analogs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Somatostatin Analogs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Somatostatin Analogs Market - Supply Chain
4.5. Global Somatostatin Analogs Market Forecast
4.5.1. Somatostatin Analogs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Somatostatin Analogs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Somatostatin Analogs Market Absolute $ Opportunity
5. Global Somatostatin Analogs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Somatostatin Analogs Market Size and Volume Forecast by Type
5.3.1. Octreotide
5.3.2. Lanreotide
5.3.3. Pasireotide
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Somatostatin Analogs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Somatostatin Analogs Market Size and Volume Forecast by Application
6.3.1. Acromegaly
6.3.2. Carcinoid Syndrome
6.3.3. Neuroendocrine Tumor
6.3.4. Cushing Syndrome
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Somatostatin Analogs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Somatostatin Analogs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Somatostatin Analogs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Somatostatin Analogs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Somatostatin Analogs Demand Share Forecast, 2019-2029
9. North America Somatostatin Analogs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Somatostatin Analogs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Somatostatin Analogs Market Size and Volume Forecast by Application
9.4.1. Acromegaly
9.4.2. Carcinoid Syndrome
9.4.3. Neuroendocrine Tumor
9.4.4. Cushing Syndrome
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Somatostatin Analogs Market Size and Volume Forecast by Type
9.7.1. Octreotide
9.7.2. Lanreotide
9.7.3. Pasireotide
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Somatostatin Analogs Demand Share Forecast, 2019-2029
10. Latin America Somatostatin Analogs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Somatostatin Analogs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Somatostatin Analogs Market Size and Volume Forecast by Application
10.4.1. Acromegaly
10.4.2. Carcinoid Syndrome
10.4.3. Neuroendocrine Tumor
10.4.4. Cushing Syndrome
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Somatostatin Analogs Market Size and Volume Forecast by Type
10.7.1. Octreotide
10.7.2. Lanreotide
10.7.3. Pasireotide
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Somatostatin Analogs Demand Share Forecast, 2019-2029
11. Europe Somatostatin Analogs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Somatostatin Analogs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Somatostatin Analogs Market Size and Volume Forecast by Application
11.4.1. Acromegaly
11.4.2. Carcinoid Syndrome
11.4.3. Neuroendocrine Tumor
11.4.4. Cushing Syndrome
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Somatostatin Analogs Market Size and Volume Forecast by Type
11.7.1. Octreotide
11.7.2. Lanreotide
11.7.3. Pasireotide
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Somatostatin Analogs Demand Share, 2019-2029
12. Asia Pacific Somatostatin Analogs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Somatostatin Analogs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Somatostatin Analogs Market Size and Volume Forecast by Application
12.4.1. Acromegaly
12.4.2. Carcinoid Syndrome
12.4.3. Neuroendocrine Tumor
12.4.4. Cushing Syndrome
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Somatostatin Analogs Market Size and Volume Forecast by Type
12.7.1. Octreotide
12.7.2. Lanreotide
12.7.3. Pasireotide
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Somatostatin Analogs Demand Share, 2019-2029
13. Middle East & Africa Somatostatin Analogs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Somatostatin Analogs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Somatostatin Analogs Market Size and Volume Forecast by Application
13.4.1. Acromegaly
13.4.2. Carcinoid Syndrome
13.4.3. Neuroendocrine Tumor
13.4.4. Cushing Syndrome
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Somatostatin Analogs Market Size and Volume Forecast by Type
13.7.1. Octreotide
13.7.2. Lanreotide
13.7.3. Pasireotide
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Somatostatin Analogs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Somatostatin Analogs Market: Market Share Analysis
14.2. Somatostatin Analogs Distributors and Customers
14.3. Somatostatin Analogs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Peptron
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Chiasma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Ipsen Biopharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ...
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
